NanoViricides Inc. to Present at The NSTI Nanotech 2008 Conference in Boston
June 04, 2008 07:00 AM US Eastern Timezone
EKC, Other Results, as well as Broad-Spectrum Nanoviricides Capability to be Discussed
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), said that it has been invited to make a presentation outlining the broad-spectrum capability of its nanoviricides at the NSTI Nanotech 2008 Conference in Boston, MA, on Thursday, June 5 (http://www.nsti.org/Nanotech2008/thursday.html). NSTI Nanotech is a highly renowned annual international scientific conference with a major track on nanomedicines (http://www.nsti.org/Nanotech2008/).
“We will present some of the EKC data at this conference,” said Eugene Seymour, MD, MPH, CEO of the Company, adding, “The fact that we have broad-spectrum nanoviricides that are highly effective, and not a one-virus-one-drug approach, is very significant in battling diseases such as viral conjunctivitis which can be caused by many different types of viruses.”
The Company has previously reported that a rapid and significant clinical response using a nanoviricide drug candidate eye-drop treatment was seen in the eyes of test animals. The most effective drug candidate was a broad-spectrum nanoviricide that has previously exhibited very high effectiveness against a broad range of viruses in animal studies including influenza and rabies. It also demonstrated excellent effectiveness in cell culture studies against bird flu (H5N1). The Company utilized intelligent bioinformatics tools to design the ligand (targeting molecule) used to construct this nanoviricide. This ligand was designed to achieve a strong binding activity against a broad range of different types of viruses.
There is currently no effective treatment for EKC nor are there any effective treatments for bird flu (H5N1), or rabies, either. Bird flu has spread further this year with Bangladesh reporting its first human case (http://hosted.ap.org/dynamic/stories/A/AS_MED_BANGLADESH_BIRD_FLU_AS OL-?SITE=AP&SECTION=HOME&TEMPLATE=DEFAULT&CTIME=2008-05-22-11-51-52).
EKC or epidemic kerato-conjunctivitis is a very severe and highly contagious pink eye disease. It is most often caused by certain adenoviruses. However, some other viruses also cause similar conjunctivitis diseases. The Company anticipates that the eye-drop formulation that was successful against adenoviral EKC may also work well against the less severe forms of viral-induced conjunctival diseases (pink eye). While the Company currently has no approved product for the treatment of EKC and viral conjunctivitis, the treatment and prophylaxis market for these two classes of eye disease is expected to be of the order of several billion dollars annually.
The Company is working on making available some of the photographs from the EKC animal study at their website shortly.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.